Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030047/S055

PRECISE PRO RX Nitinol Stent System

Cordis US Corporation · Decision date Jun 5, 2026

FDA DECISIONP030047/S055

What did the FDA approve?

FDA records P030047/S055 as a supplement to PMA P030047, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jun 5, 2026.

FDA approval order statement

Approval for labeling updates.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Jun 5, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P030047/S055
Regulatory pathway
PMA supplement
Product code
NIM
Decision code
APPR
Decision date
Jun 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, carotid.

Product code
NIM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P030047/S051 · Related supplement

    PRECISE PRO RX Nitinol Stent System; PRECISE PRO Transcarotid Stent System

  2. P030047/S052 · Related supplement

    PRECISE PRO Rx Nitinol Stent System; PRECISE PRO Transcarotid Stent System

  3. P030047/S053 · Related supplement

    PRECISE PRO RX Nitinol Stent System; PRECISE PRO Transcarotid Stent System

  4. P030047/S055 received

    Application receipt date recorded by FDA.

  5. P030047/S055 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P030047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030047

Explore the linked device profile

Other records with product code NIM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cordis US Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
14201 NW 60th Ave., Miami Lakes, FL, 33014

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records